Randomised, Double- Blind, Cross-over Efficacy and Safety Comparison of Three Different Doses of Tiotropium Administered Once Daily Versus Placebo in Patients With Moderate Persistent Asthma.
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2010-11-03
- Last Posted Date
- 2013-12-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 149
- Registration Number
- NCT01233284
- Locations
- 🇩🇪
205.380.49010 Boehringer Ingelheim Investigational Site, Berlin, Germany
🇺🇦205.380.38003 Boehringer Ingelheim Investigational Site, Kharkiv, Ukraine
🇺🇦205.380.38004 Boehringer Ingelheim Investigational Site, Kharkiv, Ukraine
PETRO Stroke Prevention in Patients With AF by Treatment With Dabigatran, With and Without Aspirin, Compared to Warfarin
- Conditions
- Atrial Fibrillation
- Interventions
- First Posted Date
- 2010-10-25
- Last Posted Date
- 2014-05-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 502
- Registration Number
- NCT01227629
- Locations
- 🇺🇸
1160.20.10015, Baltimore, Maryland, United States
🇩🇰1160.20.45010, Aalborg, Denmark
🇩🇰1160.20.45005 Aarhus Sygehus, Aarhus C, Denmark
BIBR 1048 Dose Range Finding Study in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Hip or Knee Replacement Surgery
- First Posted Date
- 2010-10-21
- Last Posted Date
- 2014-05-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1973
- Registration Number
- NCT01225822
- Locations
- 🇦🇹
1160.19.43001 A.ö. Krankenhaus d. Statutarstadt Wiener Neustadt, Wr. Neustadt, Austria
🇨🇿1160.19.42006 Hospital Mlada Boleslav, Mlada Boleslav, Czech Republic
🇧🇪1160.19.32005 Virga Jesseziekenhuis, Gent, Belgium
Tiotropium Respimat Pharmacokinetic Study in COPD
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2010-10-18
- Last Posted Date
- 2014-05-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 154
- Registration Number
- NCT01222533
- Locations
- 🇧🇪
205.458.32002 Boehringer Ingelheim Investigational Site, Hasselt, Belgium
🇩🇪205.458.49001 Boehringer Ingelheim Investigational Site, Hannover, Germany
🇧🇪205.458.32003 Boehringer Ingelheim Investigational Site, Genk, Belgium
Telmisartan 80mg Non-responder Trial
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2010-10-18
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 174
- Registration Number
- NCT01222520
- Locations
- 🇯🇵
1235.36.04 Boehringer Ingelheim Investigational Site, Hiroshima, Hiroshima, Japan
🇯🇵1235.36.02 Boehringer Ingelheim Investigational Site, Shinjuku-ku, Tokyo, Japan
🇯🇵1235.36.01 Boehringer Ingelheim Investigational Site, Chuo-ku,Tokyo, Japan
Single Rising Dose (SRD), Multiple Rising Dose (MRD) Study of BI 671800 in Healthy Asian Volunteers
- Conditions
- AsthmaRhinitis, Allergic, Perennial
- Interventions
- Drug: BI 671800Drug: placebo
- First Posted Date
- 2010-10-07
- Last Posted Date
- 2013-11-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 73
- Registration Number
- NCT01216384
- Locations
- 🇰🇷
1268.15.8201 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of
Pharmacokinetics, Safety and Tolerability of BI 671800 HEA Given Over 7 Days. A Randomised, Double Blind, Placebo Controlled Within Dose Groups Phase I Study in Healthy Male and Female Volunteers.
- Conditions
- Healthy
- Interventions
- Drug: BI 671800Drug: Placebo
- First Posted Date
- 2010-10-07
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT01215773
- Locations
- 🇩🇪
1268.59.1 Boehringer Ingelheim Investigational Site, Ingelheim, Germany
Relative Bioavailability of Two Different Batches of a Linagliptin / Metformin Combination Tablet in Healthy Volunteers
- Conditions
- Healthy
- Interventions
- Drug: Linagliptin/Metformin (standard batch)Drug: Linagliptin/Metformin (side batch)
- First Posted Date
- 2010-10-07
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 40
- Registration Number
- NCT01216397
- Locations
- 🇩🇪
1288.6.1 Boehringer Ingelheim Investigational Site, Ingelheim, Germany
Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Metformin Therapy
- First Posted Date
- 2010-10-06
- Last Posted Date
- 2016-08-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 306
- Registration Number
- NCT01215097
- Locations
- 🇨🇳
1218.65.86008 Boehringer Ingelheim Investigational Site, Dalian, China
🇨🇳1218.65.86007 Boehringer Ingelheim Investigational Site, Beijing, China
🇨🇳1218.65.86011 Boehringer Ingelheim Investigational Site, Chongqing, China
BIBW 2992 (Afatinib) and Vinorelbine in Japanese Patients With Advanced Solid Tumours
- Conditions
- Neoplasms
- Interventions
- First Posted Date
- 2010-10-05
- Last Posted Date
- 2014-07-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 17
- Registration Number
- NCT01214616
- Locations
- 🇯🇵
1200.84.003 Boehringer Ingelheim Investigational Site, Chuo-ku, Osaka, Osaka, Japan
🇯🇵1200.84.004 Boehringer Ingelheim Investigational Site, Kashiwa, Chiba, Japan
🇯🇵1200.84.002 Boehringer Ingelheim Investigational Site, Sakyo-ku, Kyoto, Kyoto, Japan